Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) begins acting within hours of your first injection, but the effects most people notice (a quieter appetite, feeling full sooner) typically build over the first few weeks of treatment rather than appearing on day one. That gap between pharmacology and lived experience is the thing worth understanding. Mounjaro is a prescription-only medicine; a clinician assesses whether it is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro SmPC, available on the eMC, confirms that tirzepatide reaches peak plasma concentration somewhere between 8 and 72 hours after a subcutaneous injection, a wide window that reflects genuine variation between individuals. By day seven the medicine is still present in meaningful concentrations, which is why once-weekly dosing works at all. So in purely pharmacological terms, Mounjaro is doing something within hours. The question most people are really asking, though, is different: when will I feel it?
Those two things (pharmacological action and perceptible effect) do not arrive at the same moment. GIP and GLP-1 receptor activation affects gastric emptying and appetite signalling steadily, not in a single surge. The body does not announce a threshold being crossed. What people describe instead is a slow reduction in the background noise of hunger, often noticed first at mealtimes or when the fridge door opens and they realise they are not particularly interested.
If you are wondering exactly how the first 24 hours unfold after your initial injection, there is a detailed account on our first 24 hours on Mounjaro page.
SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults and tracked outcomes over 72 weeks. The primary weight-loss endpoints were assessed at that 72-week mark, not at week one or week four. That is not because the researchers missed the early window; it is because weight loss from a GLP-1/GIP medicine is a cumulative process. The trial reported average body-weight reductions of around 20–21% at the 15 mg dose over the full study duration, with participants titrating through lower doses first.
What this means practically: there is no single clinical answer to "how many hours before Mounjaro kicks in" because the medicine's meaningful effect is dose-dependent and accumulates across a titration schedule that typically spans several months. The 2.5 mg starting dose is there to let your system adjust, nausea is common and the first pen's job is tolerability, not maximal suppression. Appetite-related changes become more pronounced as the dose increases, and many people report the clearest shift somewhere between weeks four and eight, often coinciding with their first or second dose step-up.
Curious about the documented results at different stages? Our Mounjaro before and after page sets out what the evidence shows across the titration journey.
Here is something worth knowing if you are a few hours post-injection and wondering whether anything is happening: gastrointestinal effects often precede the noticeable appetite changes. Nausea, a mild sensation of fullness, or slight indigestion can appear on the same day as your first dose. This is not the "kick-in" people are hoping for, but it is evidence the medicine is active. The NHS tirzepatide medicines page lists nausea, diarrhoea, constipation, reflux and fatigue as common early effects, typically most pronounced in the first few days after each new dose and settling within a week or two for most people.
Practically speaking: plan your injection timing with those early hours in mind. Some people find injecting on a day when they have lighter commitments helps. There is a separate guide covering whether taking Mounjaro before bed affects tolerability, worth reading before you settle on a routine. The side effects are not the goal, but they are real pharmacological evidence that tirzepatide is working at a receptor level, even before the scale moves.
For a fuller checklist of practical steps to take before your first dose, the what to do before starting Mounjaro page covers storage, preparation and injection technique in plain terms.
One thing that catches people off guard: because Mounjaro's effect builds over months, the cost of treatment is a recurring consideration, not a one-off. Understanding what you are paying for across the titration schedule matters. Our weight-loss treatments page sets out exactly what is included (consultation, prescription, clinical re-review before every repeat, and next-working-day delivery) so there are no surprises as the weeks go on.
If you would like to explore the full clinical profile of tirzepatide before committing to a consultation, the tirzepatide overview covers the mechanism, the trial data and the licensed indications in detail. And if you are already thinking about starting, reading through what to do before taking Mounjaro is a useful final check. Many people tell our prescribers they wish they had set realistic expectations about the timeline sooner, the medicine works, but it works steadily, not overnight.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.